Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
10 juin 2022 08h00 HE
|
Vor Biopharma
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited...
Vor Bio to Participate in Upcoming Investor Conferences
01 juin 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
12 mai 2022 16h15 HE
|
Vor Biopharma
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing...
Vor to Participate in Two Upcoming Investor Conferences
05 mai 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
25 avr. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that two abstracts have been accepted for poster...
Vor Bio Announces Retirement of Chief Medical Officer
14 avr. 2022 16h15 HE
|
Vor Biopharma
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer...
Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
14 mars 2022 16h30 HE
|
Vor Biopharma
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022New program VCAR33ALLO using healthy donor-derived T cells IND submission expected in 1H 2023Cash runway extended...
Vor to Participate in Three Upcoming Investor Conferences
28 févr. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
11 févr. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor to Participate in Two Upcoming Investor Conferences
04 janv. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...